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Understanding the function of genes mutated in hereditary forms of Parkinson’s disease yields insight into
disease etiology and reveals new pathways in cell biology. Although mutations or variants in many genes
increase the susceptibility to Parkinson’s disease, only a handful of monogenic causes of parkinsonism
have been identified. Biochemical and genetic studies reveal that the products of two genes that are mutated
in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to
govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved
in Parkinson’s disease. PINK1 accumulates on the outer membrane of damaged mitochondria, activates
Parkin’s E3 ubiquitin ligase activity, and recruits Parkin to the dysfunctional mitochondrion. Then, Parkin
ubiquitinates outer mitochondrial membrane proteins to trigger selective autophagy. This review covers
the normal functions that PINK1 and Parkin play within cells, their molecular mechanisms of action, and
the pathophysiological consequences of their loss.Parkinson’s disease (PD) affects 1%–2%of the population and is
the second most common neurodegenerative disease (de Rijk
et al., 1995). Four cardinal signs characterize PD, rigidity, brady-
kinesia, postural instability, and tremor (Lang and Lozano,
1998a, 1998b), that stem from the progressive loss of dopami-
nergic neurons in the substantia nigra pars compacta (SN).
Motor symptoms appear when approximately 50%–60% of
these neurons degenerate, causing a 70%–80% depletion of
dopamine (DA) levels in the dorsal striatum (Lang and Lozano,
1998a, 1998b). The remaining SN neurons typically contain in-
clusions in the cytoplasm called Lewy bodies that immunostain
for a-synuclein and other proteins (Spillantini et al., 1998). There
is no cure, and the best treatment options only provide symp-
tomatic relief with no abatement or reversal of disease progres-
sion. Although a large majority of diagnosed PD cases are
idiopathic, autosomal dominant and recessive familial forms
have been identified. By understanding how monogenic forms
of PD lead to cell dysfunction and neuron death, researchers
are identifying causes of parkinsonism and new pathways in
cell biology.PARK2 (Parkin) and PARK6 (PINK1) Identification
In 1997, a genetic linkage analysis showed that chromosome
6q25.2-27 harbored an unidentified gene responsible for auto-
somal recessive juvenile parkinsonism (AR-JP) in 13 Japanese
families (Matsumine et al., 1997). One year later, the Shimizu
group cloned the AR-JP gene, PARK2, and identified more
Japanese AR-JP patients with either an exon 4 or a large-scale
deletion between exons 3 and 7 (Kitada et al., 1998). Other
patients of various ethnicities with early-onset PD were soon
reported to also harbor PARK2mutations with varying deletions
or point mutations that cause PARK2 protein loss of function
(Hattori et al., 1998a, 1998b; Leroy et al., 1998; Lu¨cking et al.,1998). PARK2 contains 12 exons that encode the 465 amino
acid protein, Parkin (Kitada et al., 1998). Parkin is an E3 ubiquitin
ligase with an amino-terminal ubiquitin-like (Ubl) domain and a
carboxyl-terminal ubiquitin ligase domain (Hristova et al., 2009;
Shimura et al., 2000).
The second gene to be identified in early-onset recessive PD
cases was found in 2001 within a large Italian pedigree on chro-
mosome 1 at the PARK6 locus (Valente et al., 2001, 2002b).
These PARK6 mutation patients had symptoms clinically iden-
tical to those of patients with sporadic forms of PD (Bentivoglio
et al., 2001; Valente et al., 2002a). The 8 exon PARK6 gene
encodes the 581 amino acid protein phosphatase and tensin
homolog (PTEN)-induced kinase 1 (PINK1) (Valente et al.,
2004), a name stemming from its prior identification in a screen
for proteins transcriptionally upregulated by exogenous PTEN
overexpression (Unoki and Nakamura, 2001). The protein
sequence reveals a predicted C-terminal kinase domain and a
mitochondrial targeting sequence at the N terminus, suggesting
that it is imported into the mitochondria, which is consistent
with its mitochondrial localization in cells (Valente et al., 2004).
This mitochondrial localization supported prior evidence of an
involvement of mitochondrial dysfunction in the pathophysiology
of PD.Mitochondrial Dysfunction in PD
Evidence linking mitochondrial dysfunction to PD arose in the
late 1970s when accidental exposure to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), a contaminant from the syn-
thesis of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP)
(a drug used for illicit purposes), was found to cause parkin-
sonism and DA neurodegeneration (Langston et al., 1983).
Follow-up studies found that MPTP oxidized to MPP+, which is
selectively taken up into DA neurons causing an inhibition of I,Neuron 85, January 21, 2015 ª2015 Elsevier Inc. 257
Figure 1. Model of Parkin-Induced Mitophagy
Dysfunctional mitochondria (yellow mitochondrion) fail to import and degrade
PINK1 stabilizing it on the outer mitochondrial membrane (OMM). After PINK1
accumulation, PINK1 phosphorylates ubiquitin and Parkin to activate Parkin’s
E3 ligase activity. Parkin ubiquitinates substrates on the outer mitochondria for
two divergent processes: autophagosome recruitment and ubiquitin protea-
some degradation of ubiquitinatedmitochondrial substrates. Fis1 is a receptor
on the outer membrane that binds two proteins, TBC1D15 and TBC1D17, to
govern the developing LC3 isolation membrane to generate the autophago-
some around the damaged mitochondria. The autophagosome is then deliv-
ered to the lysosome for degradation.
Neuron
Reviewa mitochondrial respiratory chain component of the oxidative
phosphorylation (OXPHOS) machinery (Javitch et al., 1985;
Nicklas et al., 1985; Ramsay and Singer, 1986). Complex I defi-
ciency also was found in the brain, skeletal muscle, and platelets
of sporadic PD patients (Schapira et al., 1989, 1990). Pesticides
and herbicides that selectively inhibit complex I, such as rote-
none and paraquat, also cause parkinsonism in animal models258 Neuron 85, January 21, 2015 ª2015 Elsevier Inc.and possibly in man (Betarbet et al., 2000; Liou et al., 1997;
Tanner et al., 2011). These early observations indicated that
DA neurons appear particularly sensitive to mitochondrial
dysfunction.
Pathogenic mtDNA mutations also are associated with PD.
MtDNA is a 16,569-base-pair-length genome that encodes 13
genes for subunit components of OXPHOS and its own tRNAs
and rRNAs (Anderson et al., 1981). As hundreds to thousands
of copies of mtDNA reside in virtually each mammalian cell, a
state of heteroplasmy arises when different mtDNA genotypes,
such as wild-type and mutant forms, coexist within the same
cell. SN neurons from autopsies of normal-aged people and
PD patients harbor high levels of mutated mtDNA with large-
scale deletions that cause mitochondrial dysfunction (Bender
et al., 2006; Kraytsberg et al., 2006). Furthermore, mitochondrial
disease patients withmutations in polymerase g, the polymerase
responsible for mtDNA replication, excessively accumulate
mtDNA mutations and also have an increased risk of developing
PD (Luoma et al., 2004; Reeve et al., 2013). The many links be-
tween mitochondrial dysfunction and the pathogenesis of PD
stimulated interest in the role PINK1 plays in that organelle.
PINK1 and Parkin Mediate Mitophagy
Although PINK1 localizes to mitochondria and Parkin resides in
the cytosol, genetic epistasis analyses in Drosophila revealed
that both proteins work in the same pathway (Clark et al.,
2006; Park et al., 2006) and maintain mitochondrial fidelity
(Greene et al., 2003). Cell biology studies then revealed that Par-
kin is recruited from the cytosol to depolarized mitochondria to
mediate the selective autophagic removal of the damaged
organelle (mitophagy) (Narendra et al., 2008). PINK1 accumu-
lates on dysfunctional mitochondria, and its kinase activity is
required for Parkin translocation tomitochondria andmitophagy,
linking the function of these autosomal recessive PARK gene
products to the same biochemical pathway (Geisler et al.,
2010a;Matsuda et al., 2010; Narendra et al., 2010b; Vives-Bauza
et al., 2010). These findings have led to the unraveling of an
intriguing process, by which PINK1 detects mitochondrial
dysfunction and then signals Parkin to ubiquitinate specifically
the damaged mitochondria to instigate their removal by auto-
phagy. This suggests that, acting together, PINK1 and Parkin
constitute a mitochondrial quality control function (Figure 1).
Further supporting the model that mitochondrial quality control
is the essential function of PINK1 and Parkin contributing to
the prevention of parkinsonism in man, patient mutations in
both PINK1 (Geisler et al., 2010b; Narendra et al., 2010b) and
Parkin (Geisler et al., 2010a; Lee et al., 2010; Matsuda et al.,
2010; Narendra et al., 2010b) prevent PINK1 recruitment of Par-
kin to mitochondria (Figure 2 and Table 1). These results also
offer further evidence that mitochondrial dysfunction may play
a role in sporadic PD (Figure 3). Recent advances have revealed
the molecular mechanisms of PINK1 sensing mitochondrial
damage and the activation of Parkin.
PINK1 Detects Mitochondrial Damage via Selective
Proteolysis
PINK1 accumulates specifically on damaged mitochondria flag-
ging them for elimination. The damage-sensing mechanism
Figure 2. Cartoon Depiction of the Location of Mutations in Monogenic PINK1 and Parkin PD Patients
*, heterozygous mutation; ins, insertion; /, compound heterozygous; fs, frame shift; dup, duplication; TM, transmembrane domain; MTS, mitochondrial targeting
sequence; UBL, ubiquitin-like domain; RING, really interesting new gene domain; IBR, in between RING domain.
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healthy mitochondria within a cell, which is circumvented when
one mitochondrion becomes impaired, allowing PINK1 to accu-
mulate on the outer membrane of the dysfunctional mitochon-
drion (Jin et al., 2010; Meissner et al., 2011; Narendra et al.,
2010b; Figure 4). Under normal steady-state conditions, PINK1
is imported through the TOM complex of the outer mitochondrial
membrane (OMM) and into the TIM complex of the inner mito-
chondrial membrane, where it is cleaved initially by the mito-
chondrial processing peptidase (MPP) (Greene et al., 2012), as
imported proteins typically are. Then PINK1 is cleaved in its hy-
drophobic domain spanning the inner mitochondrial membrane
by the rhomboid protease, presenilin-associated rhomboid-like
protein (PARL) (Jin et al., 2010; Meissner et al., 2011). The mem-
brane-spanning domain of PINK1 is rich in Gly/Pro amino acids
that can cause kinks in membrane-spanning helices to target
them for rhomboid protease cleavage (Urban and Freeman,
2003). PARL, an inner mitochondrial membrane protease,
cleaves PINK1 between amino acids Ala103 and Phe104, gener-
ating a 52 kDa, N-terminal-deleted form of PINK1 (Deas et al.,
2011). PARL cleavage releases the N-terminal-deleted PINK1
into the cytosol where the N-terminal phenylalanine generated
by the proteolysis is identified by the N-degron type 2 E3 ubiqui-
tin ligases, according to the N-end rule, and degraded by the
ubiquitin proteasome system (Yamano and Youle, 2013). This
explains earlier work showing that proteasome inhibition stabi-
lizes a 52 kDa cleaved fragment of PINK1 (Lin and Kang, 2008).This continuous import and degradation cycle yields very low
to undetectable levels of PINK1 on healthy mitochondria
(Figure 4). However, when mitochondrial import through the
TIM complex is disrupted by mitochondrial depolarizing agents,
OXPHOS inhibitors, genetic or environmental stresses, and even
unfolded proteins, PINK1 processing by PARL is prevented
because import into the inner membrane where PARL and
MPP reside is blocked. Instead, PINK1 accumulates uncleaved
on the OMMbound to the TOM complex in a 2:1 molar ratio (Laz-
arou et al., 2012; Okatsu et al., 2013). Interestingly, this accumu-
lation of PINK1 bound to TOM is blocked completely by the loss
of a small subunit of the TOM complex, Tomm7 (Hasson et al.,
2013). Protein import through the TOM complex into the matrix
compartment is not blocked by loss of Tomm7, suggesting
that the Tomm7 subunit may be devoted to releasing OMM pro-
teins, such as PINK1, laterally through the TOM complex into the
OMM (Hasson et al., 2013). This model of how PINK1 senses
mitochondrial damage by regulated proteolysis explains how
an individually impaired mitochondrion in a milieu of healthy
mitochondria may be flagged by PINK1 (Figures 1 and 4).
Two recent papers showed that the mitochondrial matrix LON
protease also is involved in PINK1 stability. It had appeared that
loss of mitochondrial membrane potential (DJm), known to pre-
vent protein import into mitochondria through the TIM complex,
which in turn prevents PINK1 proteolysis, was the unifyingmech-
anism through which diverse mitochondrial stresses induced
PINK1 accumulation (Youle and Narendra, 2011). However, anNeuron 85, January 21, 2015 ª2015 Elsevier Inc. 259
Table 1. Summary of PARK2- and PARK6-KO Models in Comparison to Monogenic PD Patients
Gene
Inactivated Species Age of Onset
DA Neurotransmission
Defect Motor Phenotype
SN Neuron
Loss
Lewy Body
Formation Reference
PARK2 human juvenile
< 20 years;
early onset
20–40 years
DA depletion in
striatum
cardinal signs progressive absent or
present
Matsumine et al., 1997;
Kitada et al., 1998;
Pramstaller et al., 2005
PARK6 human juvenile
< 20 years;
early onset
20–40 years
DA depletion in
striatum
cardinal signs progressive absent or
present
Valente et al., 2001;
Samaranch et al., 2010
PARK2 Drosophila NA absent flight wing degeneration,
motor coordination deficits
absent unknown Greene et al., 2003
PARK2 Drosophila NA absent flight wing degeneration,
motor coordination deficits
absent unknown Pesah et al., 2004
PARK2 Drosophila 1 day (DA
neuron loss
progressive)
unknown flight wing degeneration,
motor coordination deficits
DL region unknown Whitworth et al., 2005
PARK2 Drosophila NA DA depletion flight wing degeneration,
motor coordination deficits
absent unknown Cha et al., 2005
PARK6 Drosophila NA absent flight wing degeneration,
motor coordination deficits
absent unknown Clark et al., 2006
PARK6 Drosophila 30 days decreased TH+
expression
flight wing degeneration,
motor coordination deficits
DM and DL
regions
unknown Park et al., 2006
PARK6 Drosophila 25 days DA depletion flight wing degeneration,
motor coordination deficits
DM and DL
regions
unknown Yang et al., 2006
PARK2 mouse NA increased
extracellular
DA release
beam slip motor deficit absent unknown Goldberg et al., 2003
PARK2 mouse NA decreased
DA uptake
motor coordination deficits absent unknown Itier et al., 2003
PARK2 mouse NA absent startle response deficit absent unknown von Coelln et al., 2004
PARK2 mouse NA absent absent absent unknown Perez and
Palmiter, 2005
PARK2 mouse conditional
Cre-loxP
unknown unknown yes,
lentiviral-Cre
infection
unknown Shin et al., 2011
PARK6 mouse NA evoked DA
release deficit
unknown absent unknown Kitada et al., 2007
PARK6 mouse NA DA depletion unknown absent unknown Akundi et al., 2011
DL, dorsolateral; DM, dorsomedial; NA, not applicable.
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found to stabilize PINK1 and activate Parkin without depolarizing
the inner mitochondrial membrane (Jin and Youle, 2013). If
expression of the LON protease was diminished, the levels of
PINK1 increased even further (Jin and Youle, 2013). The authors
concluded that loss of LON, which is known to help degrade
misfolded mitochondrial matrix proteins, increased misfolded
protein accumulation and thereby increased PINK1 accumula-
tion. Howmisfolded proteins cause PINK1 accumulation without
mitochondrial depolarization is yet unresolved, although it is
possible that misfolded proteins somehow inhibit TIM complex
import of PINK1 (Figure 4). Another study showed that LON-
mutant flies accumulate PINK1, although a different interpreta-
tion of the mechanism was reached (Thomas et al., 2014). The260 Neuron 85, January 21, 2015 ª2015 Elsevier Inc.Drosophila phenotype suggested that LON directly degraded
PINK1 in thematrix compartment and that loss of LONprevented
this degradation. However, this model is hard to reconcile with
the finding that PARL-processed PINK1 is degraded mainly
in the cytosol by the N-end rule (Yamano and Youle, 2013).
Nevertheless, in both flies and mammals it appears that, upon
mitochondrial damage, PINK1 becomes stabilized on the
OMM, and from there it recruits Parkin to mitochondria and
activates Parkin’s E3 ubiquitin ligase activity.
PINK1 Is a Ubiquitin Kinase
The substrate of PINK1 kinase activity mediating Parkin activa-
tion and recruitment to mitochondria was predicted to be in
the cytosol and not a mitochondrial protein, because ectopic
Figure 3. The Balance between Mitochondrial Damage and Its
Removal Contributes to PD Pathogenesis
Healthy neurons efficiently remove damaged mitochondria by mitophagy as a
quality control mechanism to ensure cell survival. Excess mitochondrial
damage (from triggers such as MPTP exposure, paraquat, and aging-induced
dysfunction) causes neuronal demise, contributing to PD pathogenesis.
Likewise, reducing the cell’s ability to remove damagedmitochondria (from the
loss of Parkin or PINK1) may cause an accumulation of these dysfunctional
organelles, leading to early-onset PD.
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pexophagy (Lazarou et al., 2012). Consistent with the cytosolic
substrate model, PINK1 directly phosphorylates Parkin at
Ser65 within the Ubl domain of Parkin, and Ser65 phosphoryla-
tion stimulates Parkin’s E3 ligase activity and recruitment to
mitochondria (Kondapalli et al., 2012; Shiba-Fukushima et al.,
2012). However, although Parkin mutated at Ser65 prevents
phosphorylation by PINK1, Ser65Ala Parkin as well as Parkin
lacking the entire Ubl domain still translocates to mitochondria
in a PINK1 kinase-dependent process, indicating that another
cytosolic PINK1 substrate is involved in Parkin activation (Kane
et al., 2014). This was initially confusing because cell-free sys-
tems displayed Parkin activation simply by mixing recombinant
PINK1 and recombinant Parkin, and critically, but not realized
at the time, E2 enzymes and ubiquitin for assessing Parkin
enzyme activity (Lazarou et al., 2013).
Three groups independently discovered that PINK1 phosphor-
ylates ubiquitin at Ser65 and that phospho-ubiquitin activates
Parkin E3 ligase activity (Kane et al., 2014; Kazlauskaite et al.,
2014b; Koyano et al., 2014). This explained all the prior in-cell
and cell-free results and fit seamlessly with the previous finding
that PINK1 phosphorylates Parkin in its Ubl domain at Ser65,
homologous to ubiquitin Ser65 (Kondapalli et al., 2012). Kane
et al. (2014) used mass spectrometry to compare PINK1-
knockout (KO) cells to wild-type cells to reveal that endogenous
PINK1 stabilized by carbonyl cyanidem-chlorophenyl hydrazine
(CCCP)-induced depolarization of mitochondria produces phos-pho-Ser65 ubiquitin. It was found that phospho-ubiquitin acti-
vates Parkin’s E3 ubiquitin ligase activity in a purified cell-free
system and that Parkin binds to phosphomimetic ubiquitin
Ser65Asp. In living cells, the inhibition of ubiquitin phosphory-
lation by the expression of ubiquitin Ser65Ala inhibits Parkin
translocation to depolarized mitochondria. The fact that phos-
pho-Ub peptides were isolated from purified mitochondrial
OMM peptides suggests that PINK1 phosphorylates ubiquitin
chains linked to OMM proteins that recruit Parkin to mitochon-
dria and activate it (Kane et al., 2014). Kazlauskaite et al.
(2014b) overexpressed PINK1 in cells treated with CCCP to
identify ubiquitin phosphorylation at Ser65 by mass spectrom-
etry. Purified recombinant PINK1 was shown to phosphorylate
ubiquitin in vitro at Ser65. It also was found that Parkin mutated
in the Ubl at Ser65 to mimic phosphorylation (Ser65Asp)
displayed greater ubiquitin ligase activity upon incubation with
phospho-ubiquitin than did wild-type Parkin, indicating that
PINK1 phosphorylation of both Parkin and ubiquitin may be
important in activation. However, both Kane et al. (2014)
and Kazlauskaite et al. (2014b) found that phosphomimetic
mutants of ubiquitin Ser65 are sufficient for Parkin activation,
whereas phosphomimetic mutants of Parkin Ser65, at least in
cells, are not.
Koyano et al. (2014) also found ubiquitin is phosphorylated
by PINK1. Like Kazlauskaite et al. (2014b), Koyano et al. (2014)
reported that Parkin Ser65 phosphorylation in combination
with ubiquitin Ser65 phosphorylation yields maximal Parkin
activity. They also showed that ubiquitin phosphomimetic
Ser65Asp further mutated at the C terminus to prevent ubiquitin
chain formation activates Parkin, indicating that phospho-ubiq-
uitin is allosteric and unrelated to thioester loading (see the
following section) on Parkin. Parkin also can conjugate both
phosphomimetic Ser65Asp and phospho-null Ser65Ala ubiquitin
mutants to mitochondrial proteins, supporting an allosteric role
as phospho-ubiquitin is neither required nor excluded as a
Parkin substrate. By immunoprecipitating ubiquitin chains, Or-
dureau et al. (2014) found PINK1 increases phospho-Ser65-
ubiquitin on mitochondria, further indicating that chains of ubiq-
uitin attached to proteins on the OMM become phosphorylated
by PINK1 and may serve as Parkin receptors on mitochondria
(Ordureau et al., 2014). Parkin binds not only to phospho-ubiqui-
tin, but also to phosphorylated ubiquitin chains. Ordureau et al.
(2014) further showed that phospho-ubiquitin binds to Ser65-
phosphorylated Parkin with a 21 times higher affinity than to
Parkin, suggesting a feedforward model of Parkin activation:
first Parkin is phosphorylated by PINK1 and then further acti-
vated by phospho-Ser65 ubiquitin. Interestingly, the active site
Cys431 of Parkin becomes exposed to Ubiquitin-vinyl sulfone
when Parkin is activated by its Ubl phosphorylation, but not by
activation by phospho-ubiquitin, suggesting that phospho-
Ser65 ubiquitin and phospho-Ser65 Parkin have different modes
of activating Parkin (Ordureau et al., 2014).
Although biochemical studies indicate that Parkin phospho-
rylation at Ser65 is required for Parkin activation, PINK1-null
and Parkin-null Drosophila can be partially rescued with
Ser65Ala Parkin, indicating that Parkin displays Ser65 phospho-
rylation-independent functions in vivo (Shiba-Fukushima et al.,
2014). Whether the Ser65Ala Parkin activity in vivo is due toNeuron 85, January 21, 2015 ª2015 Elsevier Inc. 261
Figure 4. PINK1 Is Turned over by
Sequential Proteolysis
(A) PINK1 is continuously imported into healthy
mitochondria then degraded. Mitochondrial
membrane potential drives mitochondrial import
through the TIM complex of the mitochondria
where proteases MPP and PARL cleave PINK1’s
mitochondrial targeting sequence and trans-
membrane domain. PARL’s cleavage between
Ala103 and Phe104 creates a free N-terminal
phenylalanine that is identified by N-degron type 2
E3 ubiquitin ligases targeting PINK1 to the ubiq-
uitin proteasome.
(B) Depolarization of mitochondria or blocking
mitochondrial import causes PINK1 to accumulate
on the OMM. Tomm7 is an accessory subunit of
the TOM complex that shunts and retains PINK1
on the OMM.
Figure 5. The Activation of Parkin Drives a Positive Feedback Loop
Providing Ubiquitin as a Substrate for PINK1 to Complete Mitophagy
Mitochondrial dysfunction stabilizes PINK1, enabling it to phosphorylate
ubiquitin and Parkin. This phosphorylation event activates Parkin, which
ubiquitinates substrates on the outer membrane. These ubiquitin chains on the
proteins of the OMM provide additional substrates for PINK1’s kinase activity,
causing a strong positive feedback cycle assuring mitochondrial clearance.
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presented showing that a positive feedback amplification mech-
anism drives mitophagy to completion when the product of
Parkin (ubiquitinated OMM proteins) yields substrates for
PINK1 phosphorylation that in turn further activate Parkin, lead-
ing to an amplification loop (Figure 5). The recruitment of Parkin
to mitochondria is likely initiated by PINK1 phosphorylating
ubiquitin already attached to mitochondrial outer membrane
proteins, such as mitofusin 1 (Mfn1), prior to Parkin activation.
In conclusion, phosphorylation of ubiquitin at Ser65 activates,
or derepresses, the ubiquitin ligase activity of Parkin. Ubiquitin-
phosphate is an allosteric effector of Parkin ubiquitin ligase
activity. As ubiquitin is the substrate of Parkin, this resembles
homotropic allosteric regulation in which an enzyme substrate
binds to an allosteric site on a protein to activate enzyme activity,
although, in this case, the allosteric site binds phospho-ubiquitin
generated by PINK1 and not unmodified ubiquitin. Where phos-
pho-ubiquitin binds to Parkin and the conformation of activated
Parkin remain unknown. This interplay of ubiquitin with Parkin
as both activator and substrate may relate to why a full genome
small interfering RNA screen for modifiers of Parkin translocation
yielded a rich interactome of ubiquitin pathway genes that both
accelerated and inhibited Parkin translocation after CCCP
treatment (Hasson et al., 2013).
Other substrates of PINK1 have been reported to facilitate
mitophagy by altering mitochondrial trafficking or dynamics.
PINK1 was reported to phosphorylate Miro1 at Ser156 to acti-
vate Parkin-mediated proteasomal degradation of Miro1 to
arrest mitochondrial motility (Wang et al., 2011). However, while
in agreement that Miro1 and Miro2 stability is genetically linked
and dependent upon the PINK1/Parkin pathway, others were
unable to replicate the result that PINK1 phosphorylates
Ser156 on Miro1 (Kazlauskaite et al., 2014a; Liu et al., 2012).
Mitofusin2 (Mfn2), a protein involved in OMM fusion, was identi-
fied to be phosphorylated at Thr111 and Ser442 by PINK1 to
induce Mfn2 binding to Parkin and initiate Mfn2 ubiquitination
and degradation (Chen and Dorn, 2013). However, Parkin
translocates constitutively to mitochondria in Mfn1/Mfn2-KO
cells, arguing that Mfn2 is not involved in Parkin translocation
(Narendra et al., 2008). Alternatively, PINK1 may phosphorylate
monoubiquitin and/or polyubiquitin chains covalently linked to262 Neuron 85, January 21, 2015 ª2015 Elsevier Inc.Mfn2 to recruit Parkin to mitochondria. Mitofusins are ubiquiti-
nated even in yeast that lack PINK1 and Parkin (Neutzner
et al., 2008), supporting the idea that ubiquitinated mitofusins,
among other ubiquitinated OMM proteins, may represent a
starting point for the PINK1/Parkin positive feedback ubiquitin
phosphorylation cycle (Figure 5).
PINK1 may phosphorylate other mitochondrial targets, but
they appear unrelated to the PINK1/Parkin mitophagic pathway.
Omi/HtrA2, a serine protease, and tumor necrosis factor recep-
tor-associated protein 1 (TRAP-1), a chaperone protein, both
have been reported to be targets of PINK1 (Plun-Favreau et al.,
2007; Pridgeon et al., 2007). In vitro data, however, failed to
validate Omi/HtrA2 and TRAP-1 as PINK1 targets (Kondapalli
et al., 2012). Furthermore, Omi/HtrA2 is not downstream of
the PINK1/Parkin pathway, and TRAP-1 completely rescues
PINK1-deficient, but not Parkin-mutant flies (Costa et al., 2013;
Yun et al., 2008; Zhang et al., 2013).
Figure 6. Structural Representation of Parkin
(A) Ribbon diagram of the various domains in individual colors: cyan, Ubl; gray, RING0; green, RING1; violet, IBR; blue, Rep; and bronze, RING2. The residues
Ser65 (red), Arg275 (blue), and Cys431 (yellow) are highlighted in stick representation.
(B) Juxtaposition of the ribbon diagram over a surface presentation of Parkin (Trempe et al., 2013).
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applications. The ATP analog, kinetin triphosphate, rescues
kinase activity of a patient mutant form of PINK1 and increases
wild-type PINK1 activity, revealing a new way to drug the
PINK1/Parkin pathway (Hertz et al., 2013).
Parkin E3 Ubiquitin Ligase Structure and Function
Parkin is an E3 ubiquitin ligase of an unusual class called ring-
between-ring (RBR) domain proteins that share three tandem
zinc coordination domains (Marı´n, 2009). In contrast to single
RING E3 ligases that juxtapose an E2 enzyme (linked via a
high-energy thioester bond to ubiquitin) with a protein substrate
to facilitate ubiquitin transfer from the cysteine of the E2 to a
lysine on the substrate, RBR proteins, Parkin (Lazarou et al.,
2013; Zheng and Hunter, 2013), HOIP (Smit et al., 2012), and
HHARI (Wenzel et al., 2011), all transfer ubiquitin from the E2
directly onto the RBR itself, yielding another high-energy thio-
ester intermediate, similar to HECT domain ubiquitin ligases
(Wenzel et al., 2011). Parkin has four zinc-coordinating domains,
RING0, RING1, IBR, and RING2 (Figures 2 and 6; Hristova et al.,
2009). However, only RING1 adopts the canonical ubiquitin
ligase RING domain structure that binds to E2 ubiquitin ligases
and facilitates the discharge of thioester-bound ubiquitin from
the E2 to the substrate. Like other RBR proteins, Parkin requires
activation to allow the ubiquitin-charged E2 to bind to Parkin
RING1 and transfer ubiquitin to Parkin Cys431 in RING2 to
form the HECT-like thioester intermediate (Figure 6A; Riley
et al., 2013; Trempe et al., 2013; Wauer and Komander, 2013).
Several E2s can transfer ubiquitin to PINK1-activated Parkin
in cell-free systems, including UBE2K, UBE2D1, UBE2D2,
UBE2E1, UBE2L3, and UBE2C (Kazlauskaite et al., 2014a;
Lazarou et al., 2013).
The structure of Parkin shows that the RING0, RING1, and the
IBRdomains interact and a linker domainwraps around the inter-
face of RING0 and RING1 to reach the RING2 (Riley et al., 2013;
Trempe et al., 2013;Wauer and Komander, 2013; Figure 6B). The
structure of Parkin represents the inactive or autoinhibited state
because the Cys431 site of thioester formation in RING2 (yellowin Figure 6) is occluded by the RING0domain, and the E2-binding
site on RING1 is blocked by the linker region called a repressor
element (blue helix in Figure 6; Riley et al., 2013; Trempe et al.,
2013;Wauer and Komander, 2013). A substantial conformational
change induced by phospho-ubiquitin and probably contributed
to by phospho-S65 Parkin must shift the ubiquitin-E2-binding
site on RING1 proximal to the Cys431 acceptor site on RING2.
Loading of ubiquitin onto Parkin Cys431 can be activated by
PINK1 (Lazarou et al., 2013; Zheng and Hunter, 2013), the
PINK1 substrate phosphomimetic ubiquitin Ser65Asp (Kane
et al., 2014), or the Parkin Ubl phosphomimetic Ser65Glu (Iguchi
et al., 2013). Determining the structure of activated Parkin bound
to phospho-ubiquitin will be illuminating.
The ubiquitin-like domain at the N terminus of Parkin folds
back and binds to the RING1 domain (Spratt et al., 2013; Trempe
et al., 2013). Although cell-free experiments indicated that
this Ubl domain interaction inhibits Parkin E3 ligase activity
(Chaugule et al., 2011), these experiments did not take PINK1
activation of Parkin into account. Parkin lacking the Ubl domain
is still activated by PINK1, indicating that phospho-ubiquitin
binding to Parkin doesmore than displace the Parkin Ubl domain
(Kazlauskaite et al., 2014b). However, phosphorylation of the
Parkin Ubl domain Ser65 and mutations in the linker region
between the IBR and RING2 domains near the Ubl domain may
destabilize the Ubl domain binding to RING0 and increase Parkin
sensitivity to activation (Koyano et al., 2014; Trempe et al., 2013).
Parkin conformational instability may also be linked to age-
related or PD-related decreases in Parkin solubility that could
connect the PINK1/Parkin pathway to sporadic forms of PD
(Meng et al., 2011; Pawlyk et al., 2003; Vandiver et al., 2013).
Parkin Ubiquitination: Targets and Consequences
Once activated, Parkin modifies many cytosolic and OMM pro-
teins with K48- and K63-linked ubiquitin chains (Chan et al.,
2011; Narendra et al., 2012; Sarraf et al., 2013). Quantification
of all different chain linkages reveals that Parkin primarily forms
noncanonical K6- and K11-linked chains and K48- and K63-
linked chains. Mitochondrial proteins from cells displayed moreNeuron 85, January 21, 2015 ª2015 Elsevier Inc. 263
Figure 7. Electron Micrographs of Parkin-
Induced Mitophagy and Autophagosomal
Engulfment of Mitochondria
Mouse embryonic fibroblasts overexpressing
Parkin and treated with 20 mM CCCP for 12 hr.
White arrowhead points to autophagosome
forming aroundmitochondria. Scale bar = 500 nm.
Images from Yoshii et al. (2011).
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Parkin produced more noncanonical chain linkages than K48-
and K63-linked chains (Ordureau et al., 2014).
Although the role of K6-linked chains is unknown, the K63-
linked chains appear to be involved in p62, an autophagy recep-
tor, recruitment (Geisler et al., 2010a; Narendra et al., 2010a;
Okatsu et al., 2010; Sims et al., 2012; van Wijk et al., 2012).
Although an initial report indicated that p62 is required for Par-
kin-mediated mitophagy (Geisler et al., 2010a), two groups using
p62-KOmouse embryonic fibroblasts did not find that it is essen-
tial for mitophagy (Narendra et al., 2010a; Okatsu et al., 2010).
However, the robust clumping of mitochondria that occurs
following Parkin activation is prevented in p62-KO cells. The
NBR1 ubiquitin receptor also accumulates on mitochondria after
Parkin translocation (Chan et al., 2011). However, the signifi-
cance of autophagy receptors in mediating mitophagy remains
unclear.
Parkin-generated K11- and K48-linked chains on mitochon-
dria likely lead to an endoplasmic-reticulum-associated-degra-
dation-like extraction of proteins from the OMM (OMMAD)
by p97/VCP and subsequent degradation by the proteasome
(Chan et al., 2011; Kim et al., 2013; Narendra et al., 2012; Yoshii
et al., 2011). This removal and proteolysis of OMM proteins
appears to be necessary for mitophagy (Chan et al., 2011;
Tanaka et al., 2010). Modulating the levels of OMM proteins
also controls mitochondrial motility and dynamics during the
mitophagy process. Mfn1 and Mfn2 are ubiquitinated and
degraded by the proteasome in a Parkin-dependent manner
(Gegg et al., 2010; Poole et al., 2010; Rakovic et al., 2011;
Tanaka et al., 2010; Ziviani et al., 2010). Miro1, a mitochondrial
Rho GTPase involved in trafficking, was identified and confirmed
in vitro as a Parkin substrate (Kazlauskaite et al., 2014a; Sarraf
et al., 2013; Wang et al., 2011). One group reported the ability
of Parkin to indirectly generate linear ubiquitin chains on mito-
chondria via NF-kB essential modulator (NEMO) and to elicit
protection from apoptosis by stimulating the NF-kB pathway
(Mu¨ller-Rischart et al., 2013). Thirty-six OMM substrates of Par-
kin have been identified with high confidence (Sarraf et al., 2013),
suggesting that no specific substrate is required for ubiquitin
signaling of mitophagy and that the chain-linkage type and den-
sity on mitochondria may be the trigger.264 Neuron 85, January 21, 2015 ª2015 Elsevier Inc.Mitophagy Mechanisms
Inhibiting autophagic machinery geneti-
cally or pharmacologically does not
disrupt PINK1/Parkin recruitment to the
mitochondria, but it does prevent or delay
the elimination of Parkin-ubiquitinated
mitochondria (Fogel et al., 2013; Naren-dra et al., 2008). Different assays used to assess mitophagy
have distinct advantages and drawbacks. Loss of immunostain-
ing of mitochondrial outer membrane proteins such as Tom20 is
convenient and robust, but may also reflect OMMAD, the protea-
somal degradation of OMM proteins, rather than mitophagy
(Yoshii et al., 2011). Thus, staining for inner mitochondrial mem-
brane or matrix proteins or labeling with mitotracker green is a
better measure of mitophagy than staining of outer membrane
proteins. However, inner membrane proteins are turned over at
different rates and are not necessarily precise measures of mi-
tophagy. The fluorescent protein Keima imported into the mito-
chondrial matrix changes its excitation wavelength from 440 to
586 when exposed to the acidic lysosomal pH following auto-
phagy and yields a convenient measure of mitophagy (Katayama
et al., 2011). Loss of mitochondrial DNA in nucleoids is another
clear way tomeasure loss ofmitochondria. If nucleoid loss is pre-
vented in Atg5-KO cells or by lysosomal inhibitors, such as bafi-
lomycin, one may be confident that the process is mitophagy.
Presumably, the ubiquitin chains that Parkin attaches to mito-
chondrial proteins initiate mitophagy, as is observed for other
autophagy substrates (Kirkin et al., 2009). Mitophagy (Itakura
et al., 2012), like starvation-induced autophagy (Itakura and
Mizushima, 2011), involves the independent recruitment adja-
cent to the mitochondria of three components of the autophago-
some-targeting and -expansion machinery: the serine/threonine
kinase UNC-51-like kinase 1, the membrane-spanning Atg9
protein, and LC3-associated isolation membranes. Thus, ubiqui-
tin chains attached to mitochondria seem to independently
recruit different complexes to growing isolation membranes
that expand alongside mitochondria. How these autophagy
components are recruited to isolation membranes growing
around mitochondria remains unclear, except that adaptor
proteins such as p62, NBR1, NDP52, Tax1BP1, and optineurin,
proteins that bind both to ubiquitin chains and LC3/GABARAP
family members, may be involved. On the other hand, it is
becoming clear how LC3 autophagosomal membrane gene-
ration is restricted to accurately surround the mitochondria, as
seen in electron microscopy images of Parkin-mediated mitoph-
agy (Figure 7). Two mitochondrial localized RabGAPs, TBC1D15
and TBC1D17, bound to the OMM protein Fis1 govern isolation
membrane engulfment of mitochondria. KO of either Fis1 or
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labeled autophagosomal membranes during Parkin-mediated
mitophagy (Yamano et al., 2014). Parkin activation also induces
dysregulated trafficking of LC3-bound tubules in the absence of
TBC1D15 that appears to be caused by excessive activation of
Rab7 (Yamano et al., 2014). Fis1 also regulates autophagosomal
membrane engulfment of mitochondria in vivo in C. elegans
(Shen et al., 2014).
There are tantalizing links between the mitochondrial fission
machinery andmitophagy. In yeast themitochondrial fission pro-
tein, Dnm1, homologous to mammalian Drp1, is required for
certain forms of mitophagy (Abeliovich et al., 2013; Frank et al.,
2012;Mao et al., 2013). This leads to themodel that the fragmen-
tation of mitochondria may facilitate their engulfment by auto-
phagosomes (Buhlman et al., 2014; Tanaka et al., 2010; Twig
et al., 2008) and fits with phenotypes of PINK1- and Parkin-
mutant flies that are reversed by promoting mitochondrial fission
(Deng et al., 2008; Poole et al., 2008; Yang et al., 2008).
PINK1 and Parkin can remove small pieces of vesicles from
mitochondria (McLelland et al., 2014; Yang and Yang, 2013).
This may be related to the piecemeal disposal of the nuclear en-
velope by autophagy (Krick et al., 2008), during whichmembrane
can be pinched off from larger cargo for degradation, and may
explain the selective disposal of OXPHOS complex subunits by
mitophagy (Vincow et al., 2013).
Modifiers of the PINK1/Parkin Pathway
RNAi screens have been used to uncover a number of genes that
modify Parkin translocation and/or mitophagy. Knockdown of
genes, such as HK1 and HK2 (McCoy et al., 2014), BAG4 and
HSPA1L (Hasson et al., 2013), IF1 (Lefebvre et al., 2013),
SREBF1 and FBXW7 (Ivatt et al., 2014), and SMURF1 (Orvedahl
et al., 2011), inhibits Parkin translocation, indicating that those
gene products normally participate in Parkin activation. Knock-
down of other genes, such as SIAH3 (Hasson et al., 2013), accel-
erates Parkin translocation, indicating the gene product normally
inhibits Parkin activation. Deubiquitinases (DUBs), such as
USP30 (Bingol et al., 2014) and USP15 (Cornelissen et al.,
2014), antagonize Parkin ubiquitin ligase activity by cleaving
ubiquitin chains on mitochondria. Another DUB, USP8, has
been identified to remove K6 chains from Parkin itself to posi-
tively regulate Parkin recruitment (Durcan et al., 2014). Drugging
the DUBsmay be a strategy to activate the PINK/Parkin pathway
and promote mitochondrial quality control. Targeted screens of
E2 ubiquitin ligases that may load Parkin with ubiquitin (Fiesel
et al., 2014; Geisler et al., 2014) show that UBE2D, UBE2L3,
and UBE2N participate in Parkin activity.
Affinity-binding studies indicate that AMBRA1, a protein
involved in autophagy, binds to Parkin and promotes mitophagy
(Van Humbeeck et al., 2011). Overexpression of an OMM-tar-
geted AMBRA1 also stimulates mitophagy in the presence or
absence of Parkin (Strappazzon et al., 2014). Similarly, PINK1
has been reported to bind another autophagy protein, Beclin1,
to promote autophagy (Michiorri et al., 2010).
Parkin-mediated mitophagy is also linked to apoptosis
(Winklhofer, 2014; Zhang et al., 2014). Interestingly, antiapop-
totic Bcl-2 family proteins that localize to the OMM, Bcl-xL and
Mcl-1, inhibit Parkin translocation and, therefore, suppressmitophagy (Hollville et al., 2014). Furthermore, translocation of
the proapoptotic Bcl-2 family protein Bax tomitochondria, which
is a key decision step in apoptosis (Wolter et al., 1997), is
inhibited by Parkin, perhaps contributing to Parkin inhibition of
apoptosis (Johnson et al., 2012). However, in some experimental
systems, Parkin promotes apoptosis by ubiquitinating and
inducing proteasomal degradation of Mcl-1 (Zhang et al., 2014).
Parkin Activity beyond Mitochondria
Numerous Parkin substrates were identified before Parkin’s link
to mitochondria was identified (Scarffe et al., 2014); and,
recently, Parkin also was found to ubiquitinate the transcriptional
repressor named PARIS, causing it to be degraded by the pro-
teasome and thereby inducing mitochondrial biogenesis (Shin
et al., 2011). In addition to mitochondria, Parkin has been found
to accumulate on intracellular Mycobacterium, likely to induce
their autophagy (Manzanillo et al., 2013) as a host defensemech-
anism and consistent with genetic studies linking Parkin muta-
tions to increased susceptibility to leprosy (Mira et al., 2004).
Parkin, like other RBR proteins, needs to be activated to display
ubiquitin ligase activity. A mystery for these nonmitochondrial
substrates is how Parkin’s autoinhibition is relieved. For mito-
chondrial substrates, phospho-ubiquitin produced by PINK1 ki-
nase activity is sufficient to bind and induce Parkin activation.
The kinase(s) that may activate Parkin for these proposed extra-
mitochondrial substrates remain(s) to be identified.
Physiological Triggers of Parkin Translocation
beyond CCCP
It is experimentally convenient in cultured cell lines, in primary
neurons (Ashrafi et al., 2014) and in induced pluripotent stem
cells (iPSCs) differentiated into neurons (Rakovic et al., 2013;
Seibler et al., 2011), to trigger PINK1/Parkin-mediated mitoph-
agy using pharmacological reagents to depolarize DJm, such
as CCCP, oligomycin combined with antimycin A, valinomycin,
or the photosensitizer KillerRed (Wang et al., 2012; Yang and
Yang, 2011). However, the pathway also proceeds constitutively
in neurons without chemical perturbation. Using mitochondrial-
targeted Keima to assess mitophagy, Bingol and colleagues
(2014) showed that mitophagy occurs over a period of days
(in mouse primary hippocampal neurons) without the addition
of depolarizing drugs, and that this constitutive mitophagy re-
quires endogenous PINK1 and Parkin (Bingol et al., 2014).
Genetic models of mitochondrial dysfunction that mimic path-
ophysiological processes also show that Parkin recruitment
is possible without pharmacological manipulation. Genetic loss
of Mfn1 and Mfn2 leads to a subset of mitochondria lacking
membrane potential (Chen et al., 2005) that selectively recruit
Parkin (Narendra et al., 2008). Parkin is also recruited to dysfunc-
tional mitochondrial complex I components in neurons differen-
tiated from iPSCs derived from mitochondrial encephalomyop-
athy, lactic acidosis, and stroke-like episodes (MELAS)
patients harboring the mtDNA mutation m.3243A > G (Ha¨ma¨la¨i-
nen et al., 2013). Cybrid cell lines harboring mtDNA mutations
display Parkin-mediated mitophagy in the presence of over-
expressed Parkin or upon inhibition of mammalian target of
rapamycin complex 1, mTORC1, thereby activating autophagy
(Gilkerson et al., 2012; Suen et al., 2010).Neuron 85, January 21, 2015 ª2015 Elsevier Inc. 265
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may trigger Parkin-mediated mitophagy. Overexpression of a
mutant form of ornithine transcarbamylase (DOTC), an enzyme
involved in the urea cycle, abnormally aggregates inside the
mitochondrial matrix and triggers the mitochondrial unfolded
protein response (Zhao et al., 2002). The aggregated DOTC
causes stabilization of PINK1, recruitment of Parkin tomitochon-
dria, and subsequent removal of DOTC without depolarizing
mitochondria (Jin and Youle, 2013). The DOTC expressed in
Drosophila phenocopies the muscle and flight wing mitochon-
drial defects found in PINK1- and Parkin-mutant flies, and this
phenotype can be rescued by the overexpression of Parkin in
DOTC flies (Pimenta de Castro et al., 2012).
MouseModelsManipulating Parkin or PINK1Expression
After the discovery that autosomal recessive mutations in Par-
kin lead to a loss of function, many laboratories independently
generated Parkin-KO mice to study Parkin’s function in vivo.
The first two Parkin-KO mouse models lacked exon 3 and ex-
hibited only mild phenotypes, such as the disruption of fine
motor skills and slight abnormalities in dopamine metabolism
and release, but, disappointingly, no dopaminergic neuron
loss (Goldberg et al., 2003; Itier et al., 2003). Another PARK2
mouse model with a deletion of exon 7 also did not cause mo-
tor behavioral phenotypes or DA neurodegeneration (von
Coelln et al., 2004). An exhaustive study of a Parkin-null mouse
lacking exon 2 revealed no substantial progressive motor
phenotype, no DA neurochemical defects in the striatum, and
no DA neurodegeneration (Perez and Palmiter, 2005). A condi-
tional Cre-loxP exon 7 Parkin-KO mouse was generated that
showed DA neurodegeneration after lentiviral delivery of a
GFP-tagged Cre recombinase was delivered stereotactically
to the midbrain of adult mice (Shin et al., 2011). This mouse
model showed a loss of Parkin protein and upregulation of
PARIS, which the authors concluded was responsible for DA
neuron death (Shin et al., 2011). However, it is unclear if the
DA loss in this inducible model led to locomotor deficits. It
was also untested if the conditional loss of Parkin in adults
causes neurodegeneration of other neuronal populations.
Most Parkin-KO mouse models fail to model the pathophysi-
ology of PD or display the selective DA neuron loss with the
ubiquitous loss of Parkin seen in man.
The lack of DA neurodegeneration and phenotypes that poorly
recapitulate human PD also occurred when research groups
generated PINK1-KO mouse models. The deletion in exons
4–7 of PINK1 resulted in mice displaying no signs of DA neuro-
degeneration or altered DA metabolism (Kitada et al., 2007).
A PINK1-KO mouse with exons 4 and 5 deleted displayed a pro-
gressive reduction of DA in the striatum, but these results were
puzzling because there was no evidence of DA neuron loss
(Akundi et al., 2011).
Mitochondrial impairments have been reported in the central
nervous system of Parkin- and PINK1-KO mice. Aged Parkin-
KO brains have altered expression of mitochondrial proteins
and a reduction in respiratory capacity (Palacino et al., 2004;
Periquet et al., 2005; Stichel et al., 2007). Primary PINK1-KO/
knockdown (KD) fibroblasts and neurons display reduced
DJm, impairments in respiration, Ca2+ overload inmitochondria,266 Neuron 85, January 21, 2015 ª2015 Elsevier Inc.and heightened reactive oxygen species (ROS) production (Gan-
dhi et al., 2009; Gautier et al., 2012; Heeman et al., 2011). ATP
levels are not changed in the striatum of PINK1-KOmice (Gautier
et al., 2008), whereas PINK1-KO/KD fibroblasts and neurons in
culture display impaired ATP synthesis (Heeman et al., 2011).
Mitochondria isolated from the striatum or whole brain of aged
PINK1-KO mice display defects in complex I (Gautier et al.,
2008; Morais et al., 2009), and mitochondria derived from the
brains of PINK1-KO mice have reduced calcium-buffering
capacity (Akundi et al., 2011). Despite these mitochondrial dys-
functions, Parkin- and PINK1-KO DA neurons remain viable
and functional. Even two-year-old Parkin/PINK1/DJ-1 triple-KO
mouse lacked DA neurodegeneration (Kitada et al., 2009). These
results suggest that mice compensate for the loss of PINK1 and
Parkin in DA neurons or that central nervous system neurons in
agedmice do not reach a threshold of mitochondrial dysfunction
necessary to cause detrimental phenotypes. The murine resis-
tance to PINK1-KO phenotypes does not extend to rats, as
PINK1-KO Long Evans rats present progressive DA neurode-
generation and motor phenotypes (Dave et al., 2014). Although
neuronal health appears unaffected, PINK1-KO mice develop a
progressive cardiomyopathy caused by mitochondrial dysfunc-
tion and oxidative stress (Billia et al., 2011). Consistent with
this cardiac defect, Parkin-KO mice display a more severe
phenotype than wild-type mice following experimental myo-
cardial infarction that was attributed to an accumulation of
damaged mitochondria; however, they did not display the car-
diac hypertrophy reported for PINK1-KO mice (Kubli et al.,
2013). Cardiac ischemic preconditioning also required Parkin
activity (Huang et al., 2011).
As unchallenged Parkin-KO mice lack obvious phenotypes,
several groups crossed mouse models of mitochondrial
dysfunction with the Parkin-KO mouse to assess potential roles
for Parkin in vivo in mitochondrial quality control. The phenotype
caused by deletion of mitochondrial transcription factor A
(TFAM) in DA neurons was no worse in a Parkin-KO background
(Sterky et al., 2011). This lack of synthetic phenotype indicates
that endogenous Parkin does not mitigate the effects on mito-
chondria caused by loss of TFAM. This could be due to the
essential role of TFAM in mtDNA replication that leaves no viable
pool of mitochondria for a quality control pathway to enrich.
However, one might anticipate Parkin to be recruited to the
defective mitochondria in TFAM-null cells, which was not de-
tected (Sterky et al., 2011). In addition, there are reports that
the loss of Parkin did not worsen motor phenotypes or translo-
cate, respectively, in two mouse models affecting mitochondrial
fission and fusion via Purkinje cell-specific Drp-1-KO mice
(Kageyama et al., 2012) and dopaminergic neuron-specific
Mfn2-KO mice (Lee et al., 2012). On the other hand, knocking
out choline kinase beta in the skeletal muscle of mice leads to
mitochondrial dysfunction, Parkin translocation to mitochondria,
and mitophagy (Mitsuhashi et al., 2011). In a model of muscle
atrophy following denervation, Parkin translocation to mitochon-
dria is more readily detected in vivo in ATG7-KO mice than in
wild-typemice (Furuya et al., 2014). Parkin translocation appears
to be more apparent in vivo when mitophagy is blocked down-
stream, thereby delaying the elimination of the mitochondrial
Parkin. Thus, Parkin translocation to mitochondria can occur
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mental evidence to date in mammals that Parkin rescues mito-
chondrial damage in dopaminergic neurons.
Drosophila Models Manipulating Parkin or PINK1
Expression
The absence of adequate mammalian models led to the genera-
tion of othermutant organisms to elucidate the functions of these
genes. The generation of Parkin- and PINK1-mutant flies was the
cornerstone in understanding the genetic link between these two
proteins and their relationship to mitochondrial integrity.
Parkin-mutantDrosophila display a severe flightmuscle defect
leading to locomotive behavioral problems, male sterility, and
reduced lifespan (Greene et al., 2003; Pesah et al., 2004).
Parkin-mutant flies are more susceptible to oxidative stress,
and, although not all DA neuron clusters are affected, some DA
neurons display abnormal shrinkage and morphology, and one
group reported neuron loss (Cha et al., 2005; Greene et al.,
2003, 2005; Pesah et al., 2004; Whitworth et al., 2005). Mito-
chondria are abnormal and swollen inmuscle cells lacking Parkin
activity, and this observation became important in connecting
PINK1 to Parkin mechanistically (Greene et al., 2003).
PINK1-mutant or -KD Drosophila phenocopy Parkin-mutant
flies and display the same flight muscle degeneration, sensitivity
to environmental stressors, and reduced lifespan (Clark et al.,
2006; Park et al., 2006; Yang et al., 2006). PINK1-KD and -mutant
flies also display selective DA neuron degeneration and the same
abnormal mitochondrial morphology present in Parkin-mutant
flies (Clark et al., 2006; Park et al., 2006; Yang et al., 2006).
Such strong similarities between the two models indicated that
PINK1/Parkin work in the same pathway. This was corroborated
when researchers showed that PINK1/Parkin double-mutant
flies were no worse than single-mutant flies. Overexpression of
Parkin rescued the PINK1-deficient phenotype, but not vice
versa, indicating that PINK1 acts upstream of Parkin in the
same pathway (Clark et al., 2006; Park et al., 2006; Yang et al.,
2006).
The swollen mitochondrial phenotype in both PINK1- and Par-
kin-mutant flies led to the investigation of proteins that control
mitochondrial morphology. Genetic loss of dynamin-related pro-
tein 1 (Drp1), a mitochondrial fission protein, caused synthetic
lethality in PINK1 and Parkin mutants (Deng et al., 2008; Poole
et al., 2008). The relationship with mitochondrial morphogenesis
was extended to Marf (a homolog of human Mfn) and optical
atrophy 1 (OPA1), two proteins required for mitochondrial fusion
(Deng et al., 2008; Poole et al., 2008). The silencing of Marf or
OPA1 or the overexpression of Drp1 reverted the mitochondrial
morphology and biochemical deficits exhibited in PINK1- and
Parkin-mutant flies (Deng et al., 2008; Liu et al., 2011; Park
et al., 2009; Poole et al., 2008; Yang et al., 2008). The link
between mitochondrial morphology and PINK1/Parkin is not
so clear in cultured mammalian cells as mitochondria appear
grossly normal in Parkin- and PINK1-null cells. However, as
mitophagy has been linked to mitochondrial fission in yeast
and mammals, perhaps the fission activity of PINK1 and Parkin
in flies reflects mitochondrial division to segregate debris for
autophagic elimination (Twig and Shirihai, 2011; Youle and van
der Bliek, 2012).Ubiquitous or neuronal overexpression of Parkin boosts
mitochondrial number and increases the lifespan of flies (Rana
et al., 2013). PINK1-deficient flies have deficits in complex I,
decreasedDcm, and reduced ATP levels (Liu et al., 2011; Morais
et al., 2009). Cardiomyocyte-specific Parkin-KO flies accumu-
late depolarized mitochondria that produce excess ROS (Bhan-
dari et al., 2014). Increasing mitochondrial function by facilitating
electron transport or overexpressing the yeast equivalent of
complex I rescues the PINK1-KO phenotypes, but not Parkin-
KO phenotypes in Drosophila (Vilain et al., 2012; Vos et al.,
2012). Constitutively active Ret, the receptor for glia-cell-lined-
derived neurotrophic factor, also recues only PINK1-KO flies,
restoring the mitochondrial deficits seen in this model (Klein
et al., 2014). These data suggest PINK1 has functions indepen-
dent of Parkin that may stem from PINK1 phosphorylation of
ubiquitin. Interestingly, an E3 ubiquitin ligase located on the
OMM named MULAN can compensate for Parkin activity and
appears to work in a parallel pathway to ubiquitinate mitofusin
(Yun et al., 2014).
Loss-of-function mutations in Parkin and PINK1 in Drosophila
lead to the accumulation of dysfunctional mitochondria in DA
neurons due to defective mitophagy (Burman et al., 2012).
Mass spectrometry analysis of fly neurons shows that the turn-
over rates of different subunits of mitochondrial OXPHOS com-
plexes differ despite occurring via mitophagy (Vincow et al.,
2013). This indicates that segregation of mitochondrial proteins
occurs, possibly of properly folded and functional proteins
versus misfolded or aggregated proteins. The molecular basis
of such protein segregation mechanisms leading to mitophagy
remains to be found.
PINK1 and Parkin Patients Compared to Sporadic
PD Patients
Patients with PINK1 and Parkin recessive mutations have PD
that is clinically indistinguishable from that of sporadic cases,
although they have an earlier onset of the disease (Houlden
and Singleton, 2012; Matsumine et al., 1997; Valente et al.,
2001). However, it is controversial whether or not Parkin and
PINK1 patients have a different neuropathological presentation
of Lewy body formation as compared to sporadic cases (Houl-
den and Singleton, 2012; Kitada et al., 1998; Pramstaller et al.,
2005; Samaranch et al., 2010). As a-synuclein mutations are
linked to PD, and a-synuclein is a major component of Lewy
bodies, its aggregation is a leading candidate for the etiology
of PD. Are mutations in a-synuclein and PINK1/Parkin unrelated
causes of PD or do they share common downstream targets?
Mouse models and cell culture models have attempted to eluci-
date whether there is an interaction between the PINK1/Parkin
pathway and mutant a-synuclein expression; however, to date,
it is unclear if this is the case (Choubey et al., 2011; Oliveras-
Salva´ et al., 2014; Stichel et al., 2007; von Coelln et al., 2006).
The a-synuclein aggregates can localize to mitochondria and
may cause mitochondrial dysfunction (Devi et al., 2008; Drya-
novski et al., 2013). Macroautophagy is impaired by a-synuclein
(Winslow et al., 2010), and blocking autophagy causes the accu-
mulation of damaged mitochondria in vivo (Takamura et al.,
2011). Whether mitochondrial dysfunction can lead to a-synu-
clein aggregation is unknown. Analyses of potential mechanisticNeuron 85, January 21, 2015 ª2015 Elsevier Inc. 267
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of investigation.
Concluding Remarks
Elucidating the functions of genes mutated in monogenic forms
of PD has helped researchers better grasp an understanding
of mitochondrial cell biology pathways and how these may go
awry in sporadic cases and contribute to disease (Figure 3).
Augmenting mitophagy by activating the PINK1/Parkin pathway
is an attractive target for therapeutic intervention for PD and
a variety of maternally inherited mitochondrial diseases. The
new understanding of mechanism and the importance of
mitochondrial quality control may also extend to other common
neurodegenerative diseases associated with mitochondrial
dysfunction, such as Alzheimer’s disease and amyotrophic
lateral sclerosis.
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